Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma selects Innovatix as Nyloxin distributor in US
Nyloxin is indicted for the treatment of moderate to severe (Stage 2) chronic pain. Currently, Nyloxin is available in the US as an oral spray for treating back
Nyloxin is indicted for the treatment of moderate to severe (Stage 2) chronic pain. Currently, Nyloxin is available in the US as an oral spray for treating back
The FDA has informed Perrigo that, effective immediately, the company has an acceptable regulatory status, such that any pending export license and ANDA applications from this facility will
Afinitor tablets are indicated for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin. ODAC has recommended the drug on the basis of Phase III
Medline manufactures and distributes healthcare products to more than 100,000 products to hospitals, extended care facilities, surgery centers, home care dealers and agencies. Companies manage their physical and
Magic Software is a provider of cloud and on-premise application platform and business integration solutions. Szeged Software CEO Istvan Kovacs said Magic Software’s technology has enabled them to
Uracyst is a fluid that is instilled into the bladder. It contains Sterile Sodium Chondroitin Sulfate Solution, 2.0%, and is indicated for reducing the symptoms of painful bladder
Scientific data suggests that Ganaxolone may be ideally suited to reverse FXS symptoms related to the down-regulation of the neurosteroid binding site on GABA-A ion channels. The grant
The Phase I trial is intended to investigate single escalating doses of 1, 5, or 10mg/kg of Valortim (or placebo) administered intravenously over a 120 minute infusion period.
Access Pharma will offer its CobaCyte and CobOral technology to the pharma firm for assessing gene knockdown after oral and intravenous administration. Any successful formulation developed will be
The two patents cover lipid nanoparticle (LNP) manufacturing process and the chemical modification of siRNA to mitigate immune stimulation. Tekmira Pharma said with the issuance of US patent